Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.

Literature DB >> 33620732

Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.

Zishuo I Hu¹, Azam Ghafoor¹, Manjistha Sengupta¹, Raffit Hassan¹.

Abstract

Malignant mesothelioma is an aggressive cancer with a poor prognosis and limited treatment options. For many years, the only US Food and Drug Administration-approved first-line treatment for unresectable mesothelioma was pemetrexed plus cisplatin. However, the recent approval of nivolumab plus ipilimumab as frontline treatment for patients with pleural mesothelioma marks a significant milestone for the treatment of this disease. In this review, the authors describe recent advances in therapeutic strategies for the treatment of patients with advanced, unresectable mesothelioma, highlighting the emerging use of immunotherapy and mesothelin-targeted therapies for the management of malignant mesothelioma.

Entities: Chemical

Keywords: chimeric antigen receptor T cells (CAR T cells); cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor; immunotherapy; mesothelin; mesothelioma; programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor

Mesh：

Substances：

Year: 2021 PMID： 33620732 PMCID： PMC8555868 DOI： 10.1002/cncr.33433

Source DB: PubMed Journal: Cancer ISSN： 0008-543X Impact factor: 6.921

54 in total

1. Malignant pleural mesothelioma after radiation therapy for breast cancer. A report of two additional patients.

Authors: V R Shannon; J C Nesbitt; H I Libshitz
Journal: Cancer Date: 1995-08-01 Impact factor: 6.860

2. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.

Authors: Francine Baumann; Erin Flores; Andrea Napolitano; Shreya Kanodia; Emanuela Taioli; Harvey Pass; Haining Yang; Michele Carbone
Journal: Carcinogenesis Date: 2014-11-07 Impact factor: 4.944

3. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

Authors: Evan W Alley; Juanita Lopez; Armando Santoro; Anne Morosky; Sanatan Saraf; Bilal Piperdi; Emilie van Brummelen
Journal: Lancet Oncol Date: 2017-03-11 Impact factor: 41.316

Review 4. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Authors: Raffit Hassan; Anish Thomas; Christine Alewine; Dung T Le; Elizabeth M Jaffee; Ira Pastan
Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544

5. Pemetrexed in malignant pleural mesothelioma.

Authors: Maitreyee Hazarika; Robert M White; Brian P Booth; Yong-Cheng Wang; Doo Y Lee Ham; Cheng Yi Liang; Atiqur Rahman; Jogarao V S Gobburu; Ning Li; Rajeshwari Sridhara; David E Morse; Richard Lostritto; Patricia Garvey; John R Johnson; Richard Pazdur
Journal: Clin Cancer Res Date: 2005-02-01 Impact factor: 12.531

6. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

Authors: Michele Maio; Arnaud Scherpereel; Luana Calabrò; Joachim Aerts; Susana Cedres Perez; Alessandra Bearz; Kristiaan Nackaerts; Dean A Fennell; Dariusz Kowalski; Anne S Tsao; Paul Taylor; Federica Grosso; Scott J Antonia; Anna K Nowak; Maria Taboada; Martina Puglisi; Paul K Stockman; Hedy L Kindler
Journal: Lancet Oncol Date: 2017-07-17 Impact factor: 41.316

7. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.

Authors: S Popat; A Curioni-Fontecedro; U Dafni; R Shah; M O'Brien; A Pope; P Fisher; J Spicer; A Roy; D Gilligan; O Gautschi; E Nadal; W D Janthur; R López Castro; R García Campelo; S Rusakiewicz; I Letovanec; V Polydoropoulou; H Roschitzki-Voser; B Ruepp; A Gasca-Ruchti; S Peters; R A Stahel
Journal: Ann Oncol Date: 2020-09-22 Impact factor: 32.976

8. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.

Authors: Maria J Disselhorst; Josine Quispel-Janssen; Ferry Lalezari; Kim Monkhorst; Jeltje F de Vries; Vincent van der Noort; Emmy Harms; Sjaak Burgers; Paul Baas
Journal: Lancet Respir Med Date: 2019-01-16 Impact factor: 30.700

9. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Authors: Arnaud Scherpereel; Julien Mazieres; Laurent Greillier; Sylvie Lantuejoul; Pascal Dô; Olivier Bylicki; Isabelle Monnet; Romain Corre; Clarisse Audigier-Valette; Myriam Locatelli-Sanchez; Olivier Molinier; Florian Guisier; Thierry Urban; Catherine Ligeza-Poisson; David Planchard; Elodie Amour; Franck Morin; Denis Moro-Sibilot; Gérard Zalcman
Journal: Lancet Oncol Date: 2019-01-16 Impact factor: 41.316

10. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.

Authors: Waqas Amin; Faina Linkov; Douglas P Landsittel; Jonathan C Silverstein; Michael J Becich
Journal: F1000Res Date: 2018-08-03

5 in total

Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.

1. Malignant pleural mesothelioma after radiation therapy for breast cancer. A report of two additional patients.

2. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.

3. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

Review 4. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

5. Pemetrexed in malignant pleural mesothelioma.

6. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

7. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.

8. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.

9. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

10. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.

1. The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target.

2. Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development.

3. Malignant peritoneal mesothelioma literature review: past, present, and future.

Review 4. Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.

5. Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers.